Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Earnings for Sera Prognostics, Inc. (SERA)
Earnings in 2023 (TTM): $-36,242,000
According to Sera Prognostics, Inc.'s latest financial reports the company's current earnings (TTM) are $-36,242,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Sera Prognostics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-36,242,000 | $-36,242,000 |
| 2022 | $-44,186,000 | $-44,247,000 |
| 2021 | $-35,009,000 | $-36,228,000 |
| 2020 | $-19,848,000 | $-21,607,000 |
| 2019 | $-16,521,000 | $-20,439,000 |